文献速递儿科与产科急症心脑血管急症

体外循环期间一氧化氮对心脏开放手术后神经发育结局的影响:一项随机临床试验

Neurodevelopmental Outcomes After Nitric Oxide During Cardiopulmonary Bypass for Open Heart Surgery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2025-02-03
一句话结论在6中心随机双盲试验中,体外循环氧合器加入20 ppm一氧化氮未改善先天性心脏病婴儿术后12个月的神经发育或健康相关生活质量。

这项在澳大利亚、新西兰和荷兰6个中心开展的双盲随机临床试验,纳入1364例小于2岁、因先天性心脏病接受体外循环心脏开放手术的婴儿,干预组在体外循环氧合器中加入20 ppm一氧化氮,对照组接受标准体外循环。随机化后12个月随访927例(一氧化氮组462例、标准组465例),主要终点ASQ-3总分两组无差异(均值196.6 vs 198.7,校正均数差-2.24,95%CI -11.84至7.36),次要结局亦无差异。早产(胎龄<37周)、单心室病变、先天性综合征和较长ICU住院时间与较低的ASQ-3总分相关。作者认为,经体外循环氧合器给予一氧化氮未改善术后12个月神经发育或健康相关生活质量,进一步研究应探索手术风险更高的同质队列以及更高剂量或替代治疗。

要点

  • 在6中心双盲随机试验中,体外循环氧合器给予20 ppm一氧化氮与标准体外循环相比,12个月ASQ-3总分均值196.6 vs 198.7,校正均数差-2.24(95%CI -11.84至7.36),无差异。
  • 次要结局健康相关生活质量和功能状态(PedsQL和改良儿科总体表现分类评分)在两组间无差异。
  • 校正多因素分析中,早产(胎龄<37周)、单心室病变、先天性综合征和较长ICU住院时间与较低的ASQ-3总分相关。
  • 随访927例(一氧化氮组462例、标准组465例),随访时中位年龄16.6个月(IQR 13.7-19.8),随机化后中位时间12.7个月(IQR 12.1-13.9),男性516例(55.7%)。
  • 作者认为,进一步研究应探索手术风险更高的同质队列以及更高剂量或替代治疗。

适用人群与场景

  • 纳入小于2岁、因先天性心脏病接受体外循环心脏开放手术的婴儿,共1364例,来自澳大利亚、新西兰和荷兰的6个中心。
  • 随机化后12个月时存活1318例,实际完成随访927例(一氧化氮组462例、标准组465例)。

处置流程与药物剂量

  • 干预组在体外循环氧合器中加入一氧化氮20 ppm;对照组接受标准体外循环。

研究设计与关键结果

  • 研究类型:双盲随机临床试验,6个中心,2017年7月19日至2021年4月28日随机化,预先计划的前瞻性随访于2022年8月5日完成。
  • 主要终点:ASQ-3总分,一氧化氮组均值196.6(SD 75.4)vs 标准组198.7(SD 73.8),校正均数差-2.24(95%CI -11.84至7.36)。
  • 次要终点:健康相关生活质量(PedsQL)和功能状态(改良儿科总体表现分类评分)在两组间无差异。
  • 校正多因素分析:早产(胎龄<37周)、单心室病变、先天性综合征和较长ICU住院时间与较低的ASQ-3总分相关。
  • 随访人群特征:随访时中位年龄16.6个月(IQR 13.7-19.8),随机化后中位时间12.7个月(IQR 12.1-13.9),男性516例(55.7%)。

证据类型、等级与局限

  • 证据类型:随机临床试验(双盲、6中心)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,经体外循环氧合器给予一氧化氮未改善先天性心脏病婴儿心脏开放手术后12个月的神经发育或健康相关生活质量,进一步研究应探索手术风险更高的同质队列以及更高剂量或替代治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Children with congenital heart defects who undergo cardiopulmonary bypass (CPB) surgery are at risk for delayed or impaired neurodevelopmental outcomes. Nitric oxide (NO) added to the CPB oxygenator may reduce systemic inflammation due to CPB and improve recovery from surgery, including improved neurodevelopmental outcomes.

OBJECTIVE: To investigate neurodevelopment, health-related quality of life (HRQOL), and factors associated with impaired neurodevelopment at 12 months post surgery in infants who received CPB with NO or standard CPB.

DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized clinical trial was conducted in 6 centers in Australia, New Zealand, and the Netherlands between July 19, 2017, and April 28, 2021, with a preplanned prospective follow-up 12 months postrandomization completed on August 5, 2022. The cohort included 1364 infants younger than 2 years who underwent open heart surgery with CPB for congenital heart disease.

INTERVENTIONS: The intervention group received NO 20 ppm into the CPB oxygenator. The control group received standard CPB.

MAIN OUTCOMES AND MEASURES: The primary outcome was neurodevelopment, defined as the Ages and Stages Questionnaire, Third Edition (ASQ-3) total score. Secondary outcomes were HRQOL and functional status as measured by Pediatric Quality of Life Inventory and modified Pediatric Overall Performance Category scores, respectively. Sensitivity analyses modeled the outcome for patients lost to follow-up.

RESULTS: Of 1318 infants alive 12 months after randomization, follow-up was performed in 927, with 462 patients in the NO group and 465 in the standard care group (median [IQR] age at follow-up, 16.6 [13.7-19.8] months; median [IQR] time since randomization, 12.7 [12.1-13.9] months; 516 male [55.7%]). There were no differences between the NO and standard care groups in ASQ-3 total score (mean [SD], 196.6 [75.4] vs 198.7 [73.8], respectively; adjusted mean difference, -2.24; 95% CI, -11.84 to 7.36). There were no differences in secondary outcomes. Prematurity (gestational age <37 weeks), univentricular lesions, congenital syndromes, and longer intensive care unit length of stay were associated with lower ASQ-3 total scores in adjusted multivariable analyses.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of infants with congenital heart disease, NO administered via the CPB oxygenator did not improve neurodevelopmental outcomes or HRQOL 12 months after open heart surgery. Further research should explore homogenous cohorts with higher surgical risk and higher-dose or alternative therapies.

TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12617000821392.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Long DA, Gibbons KS, Horton SB, et al. Neurodevelopmental Outcomes After Nitric Oxide During Cardiopulmonary Bypass for Open Heart Surgery: A Randomized Clinical Trial. JAMA Netw Open. 2025. PMID: 39908019. doi:10.1001/jamanetworkopen.2024.58040

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。